Veradermics announced the closing of a $75 million Series B financing, led by Suvretta Capital Management and Longitude Capital. The financing will be used to fund the ongoing pivotal clinical development of Veradermics’ lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA) or pattern hair loss (PHL).